Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation

被引：28

作者：

Khoschsorur, GholamAli ^{[1
]}

Fruehwirth, Franz ^{[1
]}

Zelzer, Sieglinde ^{[1
]}

Stettin, Mariana ^{[1
]}

Halwachs-Baumann, Gabriele ^{[1
]}

机构：

[1] Med Univ Graz, Lab Diagnost, Inst Med & Chem, A-8036 Graz, Austria

来源：

CLINICA CHIMICA ACTA | 2007年 / 380卷 / 1-2期

关键词：

comparative study; everolimus; high-performance liquid chromatograph (HPLC-tN); fluorescence polarization immunoassay (FPIA);

D O I：

10.1016/j.cca.2007.01.017

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Clinical management of transplant patients depends on therapeutic drug monitoring (TDM) and regulation of immunosuppressive therapy. TDM of whole-blood concentrations is mandatory for everolimus (ERL) dosage individualisation. We compared the new semi-automated immunoassay (Innofluor (R) Certican (R) Assay System, Seradyn Inc) using FPIA technology on Abbott TDxFLx (R) analyzers with established HPLC-UV as reference method. A total of 165 samples were analyzed from 52 transplant patients (40 kidney, 12 heart) receiving ERL or another inummosuppressive agent as part their routine care after organ transplantation. The correlation coefficient was r(2)=0.8229, and the regression equation (95% IC) yielded FPIA = 1.111 x (HPLC)+ 0.378. FPIA compared to HPLC gave a positive bias of 1.19 ng/ml. The FPIA assay so appears to have a diagnostic efficacy comparable to HPLC for assessing the risk of acute rejection in transplant recipients. However, the values of the FPIA were higher than those calculated from HPLC measurements, because of the cross-reactivity of the antibody used in the FPIA assay with the ERL metabolite and/or with sirolimus; this cross-reactivity occurs frequently when transplant patients are switched from sirolimus to ERL. (C) 2007 Elsevier B.V. All rights reserved.

引用

页码：217 / 221

页数：5

共 33 条

[1] Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection [J].

Baldelli, S ;

Zenoni, S ;

Merlini, S ;

Perico, N ;

Cattaneo, D .

CLINICA CHIMICA ACTA, 2006, 364 (1-2) :354-358

[2] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].

BLAND, JM ;

ALTMAN, DG .

LANCET, 1986, 1 (8476) :307-310

[3]

BORNSEN KO, 2001, NOVARTIS INTER REP, pR98

[4] Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry [J].

Ceglarek, U ;

Lembcke, J ;

Fiedler, GM ;

Werner, M ;

Witzigmann, H ;

Hauss, JP ;

Thiery, J .

CLINICA CHIMICA ACTA, 2004, 346 (02) :181-190

[5]

Dumont F J, 2001, Curr Opin Investig Drugs, V2, P1220

[6] Pharmacokinetics and metabolism of sirolimus [J].

Gallant-Haidner, HL ;

Trepanier, DJ ;

Freitag, DG ;

Yatscoff, RW .

THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :31-35

[7]

Holt David W., 1997, Drug Metabolism and Drug Interactions, V14, P5

[8] Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD [J].

Jacobsen, W ;

Serkova, N ;

Hausen, B ;

Morris, RE ;

Benet, LZ ;

Christians, U .

TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :514-515

[9] A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients [J].

Kahan, BD ;

Wong, RL ;

Carter, C ;

Katz, SH ;

Von Fellenberg, J ;

Van Buren, CT ;

Appel-Dingemanse, S .

TRANSPLANTATION, 1999, 68 (08) :1100-1106

[10] Therapeutic drug monitoring of inununosuppressant drugs in clinical practice [J].

Kahan, BD ;

Keown, P ;

Levy, GA ;

Johnston, A .

CLINICAL THERAPEUTICS, 2002, 24 (03) :330-350

← 1 2 3 4 →